Business Wire

ADVA

1.9.2020 09:02:12 CEST | Business Wire | Press release

Share
Colocation Australia harnesses ADVA solution to offer low-cost, long-haul connectivity

ADVA (FSE: ADV) today announced that Colocation Australia (ColoAU), a subsidiary of 5G Networks Limited (ASX: 5GN), has deployed its FSP 3000 OpenFabric™ to give customers flexible and low-cost connectivity with complete freedom to adjust capacity as required. The company’s new national wavelength product uses bandwidth sourced from a range of providers to offer cost-effective long-distance transport. By using ADVA’s open OTN cross-connect technology, ColoAU is now able to optimize links between Australia’s mainland state capital cities and Singapore to offer the lower-speed services that businesses need. Customers can select data rates ranging from 1.25Gbit/s to 50Gbit/s over OTN, Ethernet, SDH/SONET and Fibre Channel interfaces.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005020/en/

“We’re using ADVA’s technology to solve one of the key problems that small and medium-sized companies face. They no longer need to waste valuable resources in overprovisioning links that end up redundant or obsolete and are able to support growing bandwidth requirements driven by demand. By utilizing the ADVA FSP 3000 OpenFabric™, we’re able to provide elastic bandwidth offerings that can instantly be turned up or down,” said Nic Tippelt, wholesale manager, ColoAU. “Our new national wavelength product lets customers take control. It empowers them to choose high-quality, secure, point-to-point connectivity that supports ever-changing capacity needs.”

The ADVA FSP 3000 OpenFabric™ gives ColoAU and 5GN Wholesale a truly scalable end-to-end architecture and the ability to support a wide range of client interfaces for metro, inter-capital or international connectivity. It enables the company to leverage other service provider and utility networks as its own and offer a unique combination of high capacity and flexibility. The ADVA FSP 3000 OpenFabric™ features open OTN switching technology , which extends the delivery of bandwidth services throughout the network and eliminates the boundaries of legacy OTN solutions. With the new service, ColoAU has become the first company to use the openness, flexibility and scalability of ADVA’s solution in this way.

“Our FSP 3000 OpenFabric™ creates an architecture that’s open, disaggregated and completely future-proof. It gives ColoAU’s customers the freedom to efficiently transport any mix of optical services, and scale as and when needed. By utilizing other networks to flexibly offer a wide range of wavelengths, the company is empowering enterprises across Australia to harness the ideal connectivity for their business needs,” commented Erik Lindberg, VP, sales, APAC, ADVA. “ColoAU’s new national wavelength product provides businesses across Australia and Singapore with an entirely new way to access the capacity they require. It enables them to seize new opportunities without major risk and eliminates wasted capacity and unnecessary cost.”

About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About 5G Networks and Colocation Australia

Colocation Australia is a subsidiary company of 5G Networks. 5G Networks (ASX: 5GN) is a licenced telecommunications carrier operating across Australia. Our mission is to be Australia’s partner of choice for unifying a seamless digital experience for our customers across data connectivity, cloud and data centre services, underpinned by expert managed services in the business and wholesale markets. 5G Networks currently owns and operates its own nationwide highspeed data network with points of presence in all major Australian capital cities. www.5gnetworks.com.au .

Published by:

ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA

GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release

GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release

–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release

Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release

MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye